Reuters logo
BRIEF-Beigene presents preliminary Phase 1/2 clinical data on PARP inhibitor BGB-290
September 8, 2017 / 10:26 AM / in 2 months

BRIEF-Beigene presents preliminary Phase 1/2 clinical data on PARP inhibitor BGB-290

Sept 8 (Reuters) - Beigene Ltd

* Beigene presents preliminary Phase 1/2 clinical data on PARP inhibitor BGB-290 in patients with advanced solid tumors at the European Society for Medical Oncology 2017 Congress

* Beigene Ltd - “‍BGB-290 continues to demonstrate promising anti-tumor activity in preliminary data from Phase 1/2 trial”​

* Beigene Ltd - “‍BGB-290 was generally well tolerated, and all observed treatment-related adverse events were grade 3 or lower in severity”​

* Beigene Ltd says ‍four patients discontinued treatment of BGB-290 due to treatment-emergent adverse events​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below